📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Orchid Pharma Q3 FY26 Sales Down 5%, EBITDA Plummets 65% with Net Loss of ₹6 Cr
Orchid Pharma reported a weak performance for Q3 FY26, with standalone sales declining 5% year-on-year to ₹207 crore. The company's EBITDA saw a significant drop of 65%, falling to ₹13 crore, primarily due to a sharp contraction in gross margins from 43% to 31%. Consequently, the company posted a net loss of ₹6 crore for the quarter compared to a profit of ₹24 crore in the same period last year. For the nine-month period, sales are down 16% and EBITDA has halved, indicating sustained operational pressure.
Key Highlights
Standalone sales for Q3 FY26 fell to ₹207 crore from ₹217 crore in Q3 FY25, a 5% decline.
EBITDA margins contracted sharply to 6% in Q3 FY26 from 17% in the previous year's quarter.
Reported a net loss (PBT/PAT) of ₹6 crore in Q3 FY26 against a profit of ₹24 crore in Q3 FY25.
Gross margins declined significantly to 31% compared to 43% in the year-ago period due to higher COGS.
9M FY26 performance shows a 16% decline in sales and a 50% drop in EBITDA compared to 9M FY25.
💼 Action for Investors
Investors should exercise caution as the company faces significant margin pressure and declining sales. It is advisable to monitor the management's commentary regarding raw material costs and recovery timelines before making new positions.
Orchid Pharma Reports Q3 Net Loss of ₹12.6 Cr; Revenue Dips to ₹207 Cr
Orchid Pharma reported a consolidated net loss of ₹12.61 crore for the quarter ended December 31, 2025, a sharp reversal from a profit of ₹20.78 crore in the same period last year. Revenue from operations declined by 4.6% YoY to ₹207.27 crore. The bottom line was significantly impacted by an exceptional item of ₹7.11 crore related to the implementation of New Labour Codes and higher employee benefit expenses. The company is also in the process of merging its holding company, Dhanuka Laboratories, with the next NCLT hearing scheduled for March 2026.
Key Highlights
Consolidated revenue decreased to ₹207.27 crore in Q3 FY26 from ₹217.34 crore in Q3 FY25.
Reported a consolidated net loss of ₹12.61 crore versus a profit of ₹20.78 crore in the year-ago quarter.
Exceptional charge of ₹7.11 crore recognized due to past service costs under the New Labour Codes effective November 2025.
Consolidated EPS fell to ₹(2.49) from ₹4.10 YoY.
Utilized ₹332.56 crore of QIP proceeds for debt repayment and expansion, with ₹61.98 crore remaining for the Jammu facility.
💼 Action for Investors
Investors should exercise caution as the company has swung into a loss with declining year-on-year revenues. Key monitorables include the completion of the merger with Dhanuka Laboratories and the operationalization of the new Jammu manufacturing facility.
Orchid Pharma Q3 Results: Reports Consolidated Net Loss of ₹12.6 Cr; Revenue Dips 4.6% YoY
Orchid Pharma Limited reported a weak performance for the quarter ended December 31, 2025, swinging to a consolidated net loss of ₹12.61 crore from a profit of ₹20.78 crore in the year-ago period. Consolidated revenue from operations declined to ₹207.27 crore, down from ₹217.34 crore in Q3 FY25. The results were further weighed down by an exceptional item of ₹7.11 crore related to employee benefit obligations under the New Labour Codes. On the corporate front, the company's merger with its holding company, Dhanuka Laboratories, is progressing through the NCLT process.
Key Highlights
Consolidated revenue from operations decreased by 4.6% YoY to ₹207.27 crore.
Reported a consolidated net loss of ₹12.61 crore compared to a net profit of ₹20.78 crore in Q3 FY25.
Exceptional item of ₹7.11 crore recognized as past service cost due to the implementation of New Labour Codes.
Utilized ₹332.56 crore of QIP proceeds, with ₹195.46 crore directed toward debt repayment.
Amalgamation with Dhanuka Laboratories Limited is pending NCLT approval, with the next hearing on March 02, 2026.
💼 Action for Investors
Investors should be cautious given the swing to a net loss and declining revenue; focus should remain on the successful integration of the upcoming merger and the operationalization of the Jammu manufacturing facility.